Dean Laganosky, MD
Urology · Plymouth Meeting, PANPI 1861811457
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Bioprotect Medical, Inc. at 49.1% of the total. 2025 is the largest year on record at $90,245, more than ten times the $201 reported in 2019. Among urology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 478 payments — averaging $239.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bioprotect Medical, Inc.$56K
- Laborie Medical Technologies Corp.$25K
- Boston Scientific$16K
- Sumitomo Pharma America, Inc.$6K
- Procept Biorobotics Corporation$2K
- AstraZeneca$1K
- plus $7K from 45 others
What the payments were for
- Consulting fees$31,10527%
- Speaking & faculty fees$63,79056%
- Travel & lodging$8,0727%
- Food & beverage$11,51610%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIOPROTECT BALLOON IMPLANT SYSTEM$55,884
- Optilume BPH Drug Coated Balloon Catheter$25,014
- SpaceOAR VUE System - 10mL$10,652
- GEMTESA$5,508
- SpaceOAR System$3,303
- AquaBeam Robotic System$2,129
- PROVENGE$276
- iTIND System$129
- rezum Generator$126
- ANKTIVA$119
- Cook Medical Lasers$111
How this compares
$114,677 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 125 | $321,101 |
| XtandiEnzalutamide | 34 | $315,411 |
| NubeqaDarolutamide | 13 | $77,721 |
| GemtesaVibegron | 78 | $62,676 |
| MyrbetriqMirabegron | 49 | $35,521 |
| Silodosin | 120 | $9,928 |
| Finasteride | 426 | $6,920 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 52 | $5,763 |
| Tamsulosin Hcl | 333 | $5,233 |
| Methenamine Hippurate | 61 | $5,226 |
| Trospium Chloride ErTrospium Chloride | 21 | $4,803 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 225 | $4,562 |
| Dutasteride | 92 | $3,978 |
| Darifenacin ErDarifenacin Hydrobromide | 12 | $2,243 |
| Solifenacin Succinate | 31 | $1,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $6,298 | $383,777203 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $695 | $350,93283 claims |
| BayerNubeqa | $417 | $77,72113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 urology providers in Pennsylvania.
Other urology in Plymouth Meeting
- Jeffrey GordonPlymouth Meeting$17K
- John AndersonBethlehem$2.1M
- Demetrius BagleyPhiladelphia$739K
- Paul SieberLancaster$631K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Anthony DimatteoButler$189K
- Angelo BaccalaAllentown$166K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.